| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
RNS News Service
I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.
Form 38.5(b) - Willis Towers Watson
RNS
|
RNS Number : 3478C
Bank of America Merrill Lynch
16 October 2020
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
|
Name of exempt principal trader
|
|
BofA Securities, Inc.
|
|
|
Willis Towers Watson PLC
|
|
Class of relevant security to which the
dealings being disclosed relate(Note 1)
|
|
Common - IE00BDB6Q211
|
|
|
15/10/2020
|
|
2.
|
INTERESTS AND SHORT POSITIONS
|
|
(a)
|
Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)
|
|
Class of relevant security: Common
|
IE00BDB6Q211
|
|
|
Long
|
Short
|
|
Number
|
%
|
Number
|
%
|
|
|
174,928
|
0.136%
|
30,528
|
0.024 %
|
|
(2)
|
Derivatives (other than options):
|
|
33,531
|
0.026%
|
41,665
|
0.032%
|
|
(3)
|
Options and agreements to purchase/sell:
|
|
0
|
0%
|
0
|
0%
|
|
Total
|
208,459
|
0.162%
|
72,193
|
0.056%
|
|
(b)
|
Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)
|
|
Class of relevant security:
|
|
|
|
Long
|
Short
|
|
Number
|
%
|
Number
|
%
|
|
|
0
|
0%
|
0
|
0%
|
|
(2)
|
Derivatives (other than options):
|
|
0
|
0%
|
0
|
0%
|
|
(3)
|
Options and agreements to purchase/sell:
|
|
0
|
0%
|
0
|
0%
|
|
Total
|
0
|
0%
|
0
|
0%
|
|
Purchase/sale
|
Number of relevant securities
|
Price per unit
(Note 4)
|
|
Purchase
|
8,500
|
211.13 USD
|
|
Purchase
|
186
|
211.78 USD
|
|
Purchase
|
300
|
211.79 USD
|
|
Purchase
|
100
|
211.81 USD
|
|
Purchase
|
80
|
211.93 USD
|
|
Purchase
|
213
|
211.94 USD
|
|
Purchase
|
100
|
211.96 USD
|
|
Purchase
|
107
|
211.98 USD
|
|
Purchase
|
2
|
212.87 USD
|
|
Purchase
|
2
|
212.9 USD
|
|
Purchase
|
296
|
212.91 USD
|
|
Purchase
|
7
|
213.07 USD
|
|
Purchase
|
100
|
213.17 USD
|
|
Purchase
|
200
|
213.2 USD
|
|
Purchase
|
100
|
213.28 USD
|
|
Purchase
|
278
|
213.32 USD
|
|
Purchase
|
100
|
213.33 USD
|
|
Purchase
|
100
|
213.36 USD
|
|
Purchase
|
385
|
213.37 USD
|
|
Purchase
|
202
|
213.38 USD
|
|
Purchase
|
100
|
213.39 USD
|
|
Purchase
|
278
|
213.41 USD
|
|
Purchase
|
726
|
213.42 USD
|
|
Purchase
|
261
|
213.43 USD
|
|
Purchase
|
8
|
213.44 USD
|
|
Purchase
|
198
|
213.46 USD
|
|
Purchase
|
11
|
213.47 USD
|
|
Purchase
|
111
|
213.48 USD
|
|
Purchase
|
149
|
213.51 USD
|
|
Purchase
|
300
|
213.56 USD
|
|
Purchase/sale
|
Number of relevant securities
|
Price per unit
(Note 4)
|
|
Sale
|
88
|
211.78 USD
|
|
Sale
|
371
|
211.8 USD
|
|
Sale
|
1
|
211.82 USD
|
|
Sale
|
100
|
211.83 USD
|
|
Sale
|
111
|
211.86 USD
|
|
Sale
|
100
|
211.88 USD
|
|
Sale
|
600
|
211.92 USD
|
|
Sale
|
3
|
211.99 USD
|
|
Sale
|
100
|
212.02 USD
|
|
Sale
|
10
|
212.07 USD
|
|
Sale
|
57
|
212.08 USD
|
|
Sale
|
200
|
212.09 USD
|
|
Sale
|
130
|
212.1 USD
|
|
Sale
|
200
|
212.11 USD
|
|
Sale
|
185
|
212.14 USD
|
|
Sale
|
100
|
212.16 USD
|
|
Sale
|
185
|
212.24 USD
|
|
Sale
|
300
|
212.4 USD
|
|
Sale
|
107
|
212.46 USD
|
|
Sale
|
100
|
212.47 USD
|
|
Sale
|
63
|
212.62 USD
|
|
Sale
|
30
|
212.64 USD
|
|
Sale
|
100
|
212.67 USD
|
|
Sale
|
300
|
212.71 USD
|
|
Sale
|
100
|
212.76 USD
|
|
Sale
|
123
|
212.81 USD
|
|
Sale
|
371
|
212.82 USD
|
|
Sale
|
185
|
212.83 USD
|
|
Sale
|
100
|
212.84 USD
|
|
Sale
|
185
|
212.88 USD
|
|
Sale
|
100
|
212.96 USD
|
|
Sale
|
278
|
212.97 USD
|
|
Sale
|
100
|
212.98 USD
|
|
Sale
|
400
|
213.04 USD
|
|
Sale
|
277
|
213.06 USD
|
|
Sale
|
100
|
213.16 USD
|
|
Sale
|
277
|
213.2 USD
|
|
Sale
|
100
|
213.28 USD
|
|
Sale
|
100
|
213.29 USD
|
|
Sale
|
185
|
213.3 USD
|
|
Sale
|
100
|
213.31 USD
|
|
Sale
|
200
|
213.5 USD
|
|
Sale
|
100
|
213.52 USD
|
|
Sale
|
68
|
213.59 USD
|
|
Sale
|
100
|
213.6 USD
|
|
Sale
|
122
|
213.61 USD
|
|
Sale
|
119
|
213.62 USD
|
|
Sale
|
100
|
213.63 USD
|
|
Sale
|
81
|
213.64 USD
|
|
Sale
|
500
|
213.66 USD
|
|
Sale
|
296
|
213.67 USD
|
|
Sale
|
678
|
213.68 USD
|
|
Sale
|
100
|
213.69 USD
|
|
Sale
|
84
|
213.71 USD
|
|
Sale
|
300
|
213.72 USD
|
|
Sale
|
200
|
213.73 USD
|
|
Sale
|
93
|
213.78 USD
|
|
Sale
|
40
|
213.79 USD
|
|
Sale
|
147
|
213.8 USD
|
|
Sale
|
93
|
215.77 USD
|
|
Sale
|
82
|
215.86 USD
|
|
Sale
|
24
|
215.87 USD
|
|
Sale
|
200
|
215.88 USD
|
|
Sale
|
14
|
215.89 USD
|
|
Sale
|
100
|
215.91 USD
|
|
Sale
|
100
|
215.93 USD
|
|
Sale
|
100
|
215.97 USD
|
|
Sale
|
41
|
215.98 USD
|
|
Sale
|
100
|
216 USD
|
|
Sale
|
115
|
216.01 USD
|
|
Sale
|
100
|
216.11 USD
|
|
Sale
|
54
|
216.13 USD
|
|
Sale
|
140
|
216.14 USD
|
|
Sale
|
53
|
216.19 USD
|
|
Sale
|
359
|
216.23 USD
|
|
Sale
|
319
|
216.24 USD
|
|
Sale
|
294
|
216.25 USD
|
|
Sale
|
214
|
216.27 USD
|
|
Sale
|
138
|
216.3 USD
|
|
Sale
|
342
|
216.31 USD
|
|
Sale
|
432
|
216.32 USD
|
|
Sale
|
284
|
216.34 USD
|
|
Sale
|
499
|
216.35 USD
|
|
Sale
|
935
|
216.37 USD
|
|
Sale
|
285
|
216.38 USD
|
|
Sale
|
162
|
216.39 USD
|
|
Sale
|
285
|
216.4 USD
|
|
Sale
|
200
|
216.41 USD
|
|
Sale
|
600
|
216.42 USD
|
|
Sale
|
185
|
216.44 USD
|
|
Sale
|
363
|
216.45 USD
|
|
Sale
|
100
|
216.46 USD
|
|
Sale
|
100
|
216.47 USD
|
|
Sale
|
391
|
216.48 USD
|
|
Sale
|
452
|
216.49 USD
|
|
Sale
|
110
|
216.5 USD
|
|
Sale
|
200
|
216.51 USD
|
|
Sale
|
98
|
216.52 USD
|
|
Sale
|
185
|
216.54 USD
|
|
Sale
|
6
|
216.58 USD
|
|
Sale
|
8,500
|
211.617 USD
|
|
Sale
|
5,600
|
211.66 USD
|
|
Sale
|
8,500
|
213.436 USD
|
|
(b)
|
Derivatives transactions (other than options transactions)
|
|
Product name,
e.g. CFD
|
Nature of transaction
(Note 5)
|
Number of relevant securities
(Note 6)
|
Price per unit
(Note 4)
|
|
N/A
|
N/A
|
N/A
|
N/A
|
|
(c)
|
Options transactions in respect of existing relevant securities
|
|
(i)
|
Writing, selling, purchasing or varying
|
|
Product name, e.g. call option
|
Writing, selling, purchasing, varying etc.
|
Number of securities to which the option relates
(Note 7)
|
Exercise price
|
Type, e.g. American, European etc
|
Expiry date
|
Option money paid/ received per unit
(Note 4)
|
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
|
Product name,
e.g. call option
|
Number of securities
|
Exercise price per
unit
(Note 4)
|
|
N/A
|
N/A
|
N/A
|
|
(d)
|
Other dealings (including transactions in respect of new securities) (Note 3)
|
|
Nature or transaction
(Note 7)
|
Details
|
Price per unit
(if applicable)
(Note 4)
|
|
|
|
|
|
Loan
|
Loan of 500 shares
|
N/A
|
Agreements, arrangements or understandings relating to options or derivatives
|
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
|
|
None
|
|
Is a Supplemental Form 38.5(b) attached?
(Note 8)
|
No
|
|
Date of disclosure
|
16/10/2020
|
|
Contact name
|
Tolu Tade
|
|
Telephone number
|
+44207 996 3410
|
|
Name of offeree/offeror with which connected
|
Willis Towers Watson PLC
|
|
Nature of connection
(Note 9)
|
Advisor to - Willis Towers Watson PLC
|
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
ISEFIFEAISLRLII
|
|
|
|
|
|
